-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ribociclib Succinate in Pediatric Diffuse Intrinsic Pontine Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ribociclib Succinate in Pediatric Diffuse Intrinsic Pontine Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ribociclib Succinate in Pediatric Diffuse Intrinsic Pontine Glioma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Hydroxychloroquine) in Lung Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cannabidiol + Hydroxychloroquine) in Lung Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cannabidiol + Hydroxychloroquine) in Lung Disease Drug Details: IHL-675A, a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGENT-797 in Rectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGENT-797 in Rectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGENT-797 in Rectal Cancer Drug Details: AGENT-797 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risuteganib in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risuteganib in Diabetic Macular Edema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risuteganib in Diabetic Macular Edema Drug Details: Risuteganib is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risuteganib in Dry (Atrophic) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risuteganib in Dry (Atrophic) Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risuteganib in Dry (Atrophic) Macular Degeneration Drug Details: Risuteganib is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Maralixibat Chloride in Biliary Atresia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Maralixibat Chloride in Biliary Atresia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Maralixibat Chloride in Biliary Atresia Drug Details: Maralixibat chloride (Livmarli)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Maralixibat Chloride in Primary Sclerosing Cholangitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Maralixibat Chloride in Primary Sclerosing Cholangitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Maralixibat Chloride in Primary Sclerosing Cholangitis Drug Details: Maralixibat...
-
Product Insights
NewNet Present Value Model: Aligos Therapeutics Inc’s ALG-009
Empower your strategies with our Net Present Value Model: Aligos Therapeutics Inc's ALG-009 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ALG-009 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG-009 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG-009 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: ALG-055009 is...